Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

A new study highlighting the importance of a large protein complex called the exocyst in cell growth, division and ...

Researchers have developed an innovative immunotoxin (a fusion protein called GrB-Fc-KS49) designed to target epithelial membrane protein-2 (EMP2), a biomarker overexpressed in more than 75% of breast ...

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics (VERA – Research Report). The associated price ...

Jason McLellan, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at UT, will be ...

Vera Therapeutics shares are trading lower by 4.7% Monday afternoon. The company announced an exclusive license agreement ...

Because the aim of the experiment is to compare GST with a GST fusion protein, it is necessary to prepare enough precleared lysate for each reaction. Efficient mixing of reagents is the key to ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...

Vera Therapeutics (VERA) announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein ...

Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma. BioWorld Science ...